Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Sjogren’s syndrome and other autoimmune illnesses are becoming more common
4.1.1.2. Increasing awareness and the need for cutting-edge medical care
4.1.2. Restraints:
4.1.2.1. Lack of knowledge regarding the availability of the Sjogren’s syndrome drug
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1 Porter’s Five Forces Analysis
5.2 Supply Chain Analysis
5.3 Pricing Analysis
5.4 Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Cholinergic Agonists
7.2.1. Introduction
7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Off-Label Drugs
8. By Symptoms
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
8.1.2. Market Attractiveness Index, By Symptoms
8.2. Dry eyes
8.2.1. Introduction
8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Dry mouth
9. By Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.1.2. Market Attractiveness Index, By Type
9.2. Primary Sjogren’s Syndrome
9.2.1. Introduction
9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Secondary Sjogren’s Syndrome
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospitals
10.2.1. Introduction
10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Retail Pharmacy
10.4. Online Pharmacy
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Products Benchmarking
12.4. List of Key Companies to Watch
13. Company Profiles
13.1. Novartis AG
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Allergan Inc
13.3. Otsuka Pharmaceutical Co., Ltd
13.4. Santen Pharmaceutical Co., Ltd.
13.5. Nicox S.A
13.6. Argentis Pharmaceuticals, LLC
13.7. Auven Therapeutics
13.8. Abbvie Inc
13.9. Cellzome GmbH.
13.10. Biogen In.
LIST NOT EXHAUSTIVE
14. Global Sjogren’s Syndrome Market – DataM
14.1. Appendix
14.2. About Us and Application
14.3. Contact Us